Ogivri
Application withdrawn
The application for this medicine has been withdrawn
Medicine
Human
Application withdrawn
- Application under evaluation
- Withdrawal of application
Overview
On 3 August 2017, Mylan S.A.S. officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a marketing authorisation for Ogivri, for the treatment of breast cancer and gastric cancer.
Ogivri is a medicine that contains the active substance trastuzumab. It was to be available as a powder to be made up into a solution for infusion (drip) into a vein.
Ogivri was developed as a 'biosimilar' medicine. This means that it was intended to be highly similar to a biological medicine (the 'reference medicine') already authorised in the European Union called Herceptin.
Ogivri was expected to be used to treat early and metastatic breast cancer and metastatic gastric (stomach) cancer.
Ogivri was to be used only when the cancer has been shown to 'overexpress HER2': this means that the cancer produces a protein called HER2 in large quantities on the surface of the tumour cells, which makes the tumour cells grow more quickly. HER2 is overexpressed in about a quarter of breast cancers and a fifth of gastric cancers.
The active substance in Ogivri and Herceptin, trastuzumab, is a monoclonal antibody. A monoclonal antibody is an antibody (a type of protein) that has been designed to recognise and attach to a specific structure (called an antigen) that is found on certain cells in the body. Trastuzumab has been designed to attach to HER2. By attaching to HER2, trastuzumab activates cells of the immune system, which then kill the tumour cells. Trastuzumab also stops HER2 producing signals that cause the tumour cells to grow.
The company presented results of studies on the quality, safety and effectiveness of the medicine.
Two studies were carried out in healthy volunteers to investigate whether Ogivri produces the same levels of the active substance in the body as the reference medicine Herceptin and therefore has the same effect.
In a third study, Ogivri in combination with a taxane was compared with Herceptin used in combination with a taxane in 500 patients with metastatic breast cancer whose tumour cells overexpressed HER2. The study measured the number of patients who responded to treatment.
The application was withdrawn after the CHMP had evaluated the documentation provided by the company and formulated lists of questions. The company had not responded to the last round of questions at the time of the withdrawal.
Based on the review of the data at the time of the withdrawal, the CHMP had some concerns and was of the provisional opinion that Ogivri could not have been approved for the treatment of breast cancer and gastric cancer.
The CHMP's main concern was the lack of a valid certificate confirming that the manufacturing facility of the product complies with good manufacturing practice (GMP) requirements.
Therefore, at the time of the withdrawal, the CHMP was of the opinion that the company had not provided enough documentation to support the application for Ogivri.
In its letter notifying the Agency of the withdrawal of the application, the company stated that it was withdrawing the application because a GMP certificate for the manufacturing site of the product could not be obtained in the time available.
The company informed the CHMP that the withdrawal does not impact ongoing clinical trials with Ogivri.
If you are in a clinical trial and need more information about your treatment, contact the doctor who is giving it to you.
Key facts
- Name of medicine
- Ogivri
- EMA product number
- EMEA/H/C/004346
Biosimilar
This is a biosimilar medicine, which is a biological medicine highly similar to another already approved biological medicine called the ‘reference medicine’. For more information, see Biosimilar medicines.
- Marketing authorisation applicant
- Mylan S.A.S.
- Withdrawal of application
- 03/08/2017
This page was last updated on